SAFETY and efficacy of autologous bone marrow – derived mononuclear stem cell therapy in patients with severe chronic ischemic Heart Failure – rationale and design

DOI: 10.26327/RBL2018.237

Received for publication, March, 11, 2018
Accepted, October, 15, 2018

MIRUNA M. MICHEU*, NICOLETA M. POPA-FOTEA¹, VLAD BATAILA¹, NICOLETA OPRESCU¹, MARIA DOROBANTU¹,²
¹Department of Cardiology, Clinical Emergency Hospital of Bucharest, Romania
²University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
*Address for correspondence to: mirunamicheu@yahoo.com

Abstract

The main aim of this study is to explore the safety and efficacy of autologous bone marrow – derived mononuclear stem cell therapy in patients with severe chronic ischemic heart failure on short to medium-term (1-3 months). The SAFE-HF trial is a prospective, single center, two-arm, controlled trial with blind evaluation of endpoints. Target population will consist of patients with heart failure due to prior extensive myocardial infarction and left ventricle ejection fraction of less than 35% - namely the population with the highest risk of adverse events and the highest mortality. All patients will be treated with the state of the art reperfusion – primary percutaneous coronary intervention and also with guideline-based optimal medical therapy. The stem cell injection will be performed 1 to 3 months after the acute event; evolution of stem cell treated patients will be compared with matched control cases. Comprehensive assessment of outcomes will be done at 1 and 3 months follow-up; serum biomarkers, cardiac structural and physiological parameters, functional capacity and health-related quality of life will be evaluated. This pilot study possibly will serve as a foundation for designing future trials.

Keywords: Stem cell therapy, myocardial infarction, heart failure, cardiac regeneration, study design

1. Introduction

Heart failure (HF) remains a malady with one of the highest morbi-mortality and one of the highest healthcare costs of all diseases (TOWNSEND & al. [1]). Even though myocardial infarction (MI) represents the commonest cause of HF, the best treatment and management of HF secondary to MI still remains elusive. The underlying mechanisms of development and progression of HF after MI have been comprehensively discussed starting with the 1980s (HOCHMAN & al. [2]; PFEFFER & al. [3]; PFEFFER & al. [4]; COHN & al. [5]; BURCHFIELD & al. [6]; CAHILL & al. [7]; SCHIRONE & al. [8]). The left ventricle (LV) remodeling after MI is a very complex process; it has an initial and active phase, from the first week to one month, after which the process slows down but still continues up to a year with additional LV ejection fraction (LVEF) worsening. Although standard-of-care drug therapy (LEVINE & al. [9]; IBANEZ & al. [10]) may delay this process, these agents do not address the fundamental issue of cell loss. One of the latest breakthroughs in the ischemic HF treatment is stem cell therapy (SCT). A growing body of evidence suggests that transplanted stem cells (SCs) secrete a variety of growth factors and cytokines, thereby enhancing myocyte survival and migration of resident cardiac SCs to the site of injury, rather than differentiating into new fully functional cardiomyocytes and blood vessels cells (KINNAIRD
Either way, it is mandatory to target the best opportunity window for SC treatment.

2. Materials and Methods

Study Objectives

The main objective of SAFE-HF pilot study is to determine the safety of intracoronary injection of autologous bone marrow-derived mononuclear cells (BMMNCs) in patients with severe chronic ischemic HF following a MI on short to medium-term (1-3 months).

The secondary objectives are to investigate the efficacy of BMMNCs in improving cardiac function and clinical status in post-MI patients with ischemic LV dysfunction. In view of that, will be assessed the effect of SC therapy on short to medium-term (1-3 months) on the following parameters:

- clinical symptoms (New York Heart Association–NYHA–Functional Classification);
- endothelial dysfunction and prothrombotic status;
- cardiac function and perfusion;
- major adverse cardiac events (MACE);
- health-related quality of life.

Study Design and Population

The SAFE-HF trial is a prospective, single-center, two-arm, controlled trial with blind evaluation of endpoints (Figure 1).

The target population consists of patients over 18 years old with a history of MI within the past 3 months and subsequent ischemic LV dysfunction (LVEF ≤ 35%). Inclusion and exclusion criteria are detailed in Tables 1 and 2, respectively. The study protocol was approved by the institutional ethics committee; written informed consent will be obtained from all patients before enrollment.

Twenty patients will be the total number of participants included in the trial. All of them will be treated with state of the art reperfusion – primary percutaneous coronary intervention (PCI) and also with guideline-based optimal medical therapy. Patients will be assigned to either the experimental group (undergoing autologous BMMNCs transplantation, 10 patients) or control group (10 patients). The baseline evaluation will ensure not only that the subjects fulfill the inclusion and exclusion criteria, but also will be used as a reference point to determine the impact of treatment. In this regard, patients will undergo a range of tests, comprising in-depth medical history and physical checkup, routine laboratory tests, Holter ECG monitoring, two-dimensional (2D) and three-dimensional (3D) transthoracic echocardiography (TTE) and myocardial perfusion imaging-SPECT. The level of circulating endothelial progenitor cells (EPCs) and microparticles (MPs) of endothelial and platelet origin will be assessed as surrogate markers of endothelial dysfunction and procoagulant status. Since quality of life improvement represents a central public health goal, health-related quality of life will be also analyzed in relation with SCT by using Minnesota Living with Heart Failure Questionnaire (MLHFQ). SCs will be infused intracoronary 1 to 3 months after the acute event. Neither bone marrow aspiration nor sham injection will be performed in the control group.
Inclusion criteria

- 18-80 year-old
- AMI (1 to 3 months before enrollment)
- LVEF on ≤ 35% on echocardiography
- Guideline-directed medical therapy for ≥1 months

Enrollment

<table>
<thead>
<tr>
<th>Inflammation tests</th>
<th>2D &amp; 3D TTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>NT-proBNP</td>
<td>SPECT</td>
</tr>
<tr>
<td>EPCs</td>
<td>6-min walk test</td>
</tr>
<tr>
<td>MPs</td>
<td>Quality of life questionnaire</td>
</tr>
<tr>
<td>Holter ECG</td>
<td>MACE</td>
</tr>
</tbody>
</table>

Figure 1. Clinical trial flow chart. One to 3 months from a large acute myocardial infarction (AMI), patients will receive bone marrow mononuclear stem cells (BMMNCs) or no stem cell treatment according to their assigned study group. At 1 and 3 months post-infusion, the two groups will be investigated in the same manner. LVEF - left ventricular ejection fraction, NT-proBNP- N-terminal pro brain natriuretic peptide, EPCs- circulating endothelial progenitor cells, MPs - microparticles of endothelial and platelet origin, TTE - transthoracic echocardiography, SPECT- single photon computed tomography, MACE - major adverse cardiovascular events

Table 1. Inclusion criteria

1. 18 to 80 years old (inclusive)
2. AMI (1 to 3 months before enrollment) treated with successful PCI
3. Ischemic LV dysfunction with LVEF ≤ 35% on echocardiography
4. Be treated with maximal tolerated guideline-driven medical therapy in the past month
5. Ability to provide written informed consent and follow-up with protocol procedures

AMI - acute myocardial infarction, PCI - percutaneous coronary intervention, LV - left ventricle, LVEF - left ventricular ejection fraction
Table 2. Exclusion criteria

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Non-ischemic cardiomyopathy</td>
</tr>
<tr>
<td>2. Ischemic cardiomyopathy beyond proposed therapeutic window (&gt; 3 months AMI)</td>
</tr>
<tr>
<td>3. Active myocarditis</td>
</tr>
<tr>
<td>4. Constrictive pericarditis</td>
</tr>
<tr>
<td>5. Severe valvular disease (except severe mitral regurgitation of ischemic aetiology)</td>
</tr>
<tr>
<td>6. Hemodynamic instability</td>
</tr>
<tr>
<td>7. Major surgery or trauma ≤ 1 month</td>
</tr>
<tr>
<td>8. Stroke ≤ 1 month</td>
</tr>
<tr>
<td>9. Severe pulmonary disease</td>
</tr>
<tr>
<td>10. Primary haematological disease</td>
</tr>
<tr>
<td>11. Impaired renal function (serum creatinine &gt; 2.5 mg/dl) at the time of study inclusion</td>
</tr>
<tr>
<td>12. Liver dysfunction (AST and ALT &gt; 3 times the upper normal limit)</td>
</tr>
<tr>
<td>13. Hematologic abnormalities (hemoglobin &lt; 8.5 mg/dl and/ or thrombocytes &lt; 100,000/µl)</td>
</tr>
<tr>
<td>14. Active infectious disease (viral or bacterial)</td>
</tr>
<tr>
<td>15. Fever &gt; 38 °C for two consecutive days</td>
</tr>
<tr>
<td>16. Known to be positive for human immunodeficiency virus</td>
</tr>
<tr>
<td>17. History of malignancy within 5 years, without documented remission, except curatively-treated basa</td>
</tr>
<tr>
<td>18. Any other severe co-morbidity associated with a reduction in life expectancy &lt; 1 year</td>
</tr>
<tr>
<td>19. Chronic therapy with immunosuppressant medication</td>
</tr>
<tr>
<td>20. Alcohol or drug dependence</td>
</tr>
<tr>
<td>21. Female patient of child-bearing potential and not using or not willing to use effective contraception for the first 6 months of the study</td>
</tr>
<tr>
<td>22. Pregnancy or lactation</td>
</tr>
<tr>
<td>23. Unwilling and/or not able to give written informed consent</td>
</tr>
</tbody>
</table>

AMI - acute myocardial infarction, AST - aspartate aminotransferase, ALT- alanine aminotransferase

After BMMNCs injection patients will be hospitalized for at least 1 day; follow-up visits will be conducted in both groups at 4 weeks and at 3 months post-enrollment to accomplish the safety and efficacy assessments. Complete examinations will be performed at the above mentioned time points as depicted in Table 3.

Methodology of cell harvest, preparation and administration

Fifty ml of bone marrow will be aspirated from the posterior iliac crest under moderate sedation and local anesthesia by a hematologist. BMMNCs will be isolated by Ficoll–Hypaque -gradient centrifugation. After being washed twice with 0.9% NaCl and filtered, mononuclear cells will be resuspended in 0.9% NaCl enriched with 2 ml of autologous serum, obtaining a final volume of 12 ml to be injected intracoronary. Subsequently, within 8 h after harvesting, the BMMNCs suspension will be infused in 3 series of 3 minutes into the infarct-related artery by using a stop-flow technique through an over-the-wire balloon catheter positioned within the culprit-lesion stent, as described by Strauer and collegues (STRAUER & al. [13]). The number of total nucleated cells will be measured by flow cytometry, as well as the absolute counts of CD34+ and CD133+ progenitor cells.

Endpoints
Safety and efficacy endpoints will be evaluated at the 1-month and 3-months follow up visits as illustrated in Figure 1. The primary outcome measures for SCT safety will comprise the occurrence of any of the following: death, AMI, myocardial revascularization, hospitalization for HF decompensation, and sustained ventricular arrhythmias (ventricular arrhythmias lasting more than 30 seconds and/or with hemodynamic instability). Secondary safety endpoints will consist of markers depicting systemic inflammation (white blood cell count, fibrinogen, erythrocyte sedimentation rate and C-reactive protein).

**Statistical analysis**

Considering the pilot nature of our study, the sample size was not estimated based on statistical power calculations, but was considered proper for an early-phase study. Descriptive statistics for baseline characteristics recognized or supposed to be linked with outcomes will be completed. Data will be expressed as percentages for categorical variables and as mean ± standard deviation for numeric variables. Continuous variables will be tested for normal distribution by Kolmogorov-Smirnov test using Lilliefors' correlation. To compare groups, we will use Student test for quantitative variables with normal distribution, respectively chi-square test for nominal or ordinal variables. All tests will be two-sided. No substitutions will be made for missing data and analyses will be based on existing data only. Statistical analysis will be performed using SPSS software version 23. Data with p <0.05 will be considered statistically significant.

<table>
<thead>
<tr>
<th>Events</th>
<th>Enrollment</th>
<th>1 month</th>
<th>3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent SAFE-HF</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>History/physical exam</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NYHA class</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECG</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Laboratory basic analysis</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Inflammation tests</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NT-pro BNP</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>EPCs</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MPs</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>6-min walk test</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Holter ECG 24h</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>2D Echocardiography</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>3D Echocardiography</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>SPECT</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Informed consent SPECT</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Quality of life questionnaire</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Bone marrow aspiration*</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC injection*</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent for coronagraphy*</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MACE evaluation</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

*will be done only for patients in stem cells group
Reporting of events

Investigators will try to identify all adverse events through detailed anamnesis, physical examination and paraclinical investigations. Every single adverse event will be documented and promptly reported.

3. Discussion

The scientific accuracy of the study is guaranteed by the blind evaluation of endpoints and the presence of a matched control group. There are a number of methodologic challenges to be faced when designing a cardiac cell therapy study, with huge implications on the outcome. Main dares are related to selecting the patients achieving the greatest therapeutic benefit, targeting the optimal therapeutic window and choosing the appropriate endpoints (Figure 2).

Figure 2. The main challenges of stem cell therapy. SCT-stem cell therapy.

Rationale for the elected patients

Data from subgroup analyses showed that recipients of BMMNCs transplantation with lower LVEF at baseline experienced better results as regards the increase in LVEF (BRUNSKILL & al. [14]), improvement in LV volumes (JEEVANANTHAM & al. [15]), and possibly in NYHA class at long term follow-up (FISHER & al. [16]). Moreover, recent guidelines and reviews acknowledge low LVEF as a marker of worse prognosis in patients with HF (PONIKOWSKI & al [17]; JØRGENSEN & al. [18]). So, having in mind that patients with severely depressed systolic function (LVEF<35%) are those with the highest risk of adverse events and the highest mortality, we intend to target this exact population in our study.

Rationale for the selected therapeutic window

Cardiac remodeling after MI is a complex process involving the entire heart, regardless of necrotic, ischaemic or normally perfused areas; in addition, the occurring changes affect the myocardium as a whole, at cellular and molecular levels. Even though cardiac remodeling has an initial adaptive component which allows the heart to preserve its function as reaction to the acute injury, it is considered in general a deleterious process related to HF development and poor
prognosis (COHN & al. [5]). The goal of existing treatments (whether pharmacological, interventional or surgical) is therefore to prevent, slow or reverse the remodeling process. SCT is a progress in this direction, addressing myocardial hypoperfusion and loss of cardiomyocytes, the fundamental aim being the prevention or limitation of adverse ventricular remodeling by inducing heart regeneration.

When choosing the time range between administration of treatment and injury, one should bear in mind the actual chronology of changes following MI. Subsequent healing is a complex, progressive process which can be divided into three stages: 1) an initial inflammatory phase characterized by increased inflammatory cells and chemical signaling with predominance of proinflammatory cytokines, resorption of necrotic tissue and recruitment of myofibroblasts, 2) a fibrotic phase characterized by myofibroblast proliferation and collagen synthesis, and 3) a long-term remodeling phase characterized by collagen matrix stabilization and maturation (JUGDUTT & al. [19]; RICHARDSON & al. [20]). As observed in previous reviews (MICHEU & al. [21]; DOROBANTU & al. [22]) and meta-analyses (LEE & al. [23]; FISHER & al. [16]; PAVO & al. [24]; PERUZZI & al. [25]; MARTIN-RENDON [26]; FISHER & al. [27]; FISHER & al. [28]), the majority of conducted trials delivered the SCs in the first days and weeks after MI - when the most active phase of LV remodeling takes place-or months, even years after MI – when the scar is already organized.

On the other hand, very few clinical trials (ANG & al. [29]; BARTUNEK & al. [30]; HELDMAN & al. [31]; MOZID & al. [32]; KIM & al. [33]) addressed the therapeutic window ranging from 1 to 3 months from the MI, a time period when the impact of intervention should not be ignored.

So, even though at first glance it would look like initial days after AMI are the optimal choice for administering SCT, there are a number of specifics which we have considered when choosing the therapeutic window: (1) the increased local inflammatory reaction through synergistic action of processes - such as reactive oxygen species production and damage-associated molecular patterns - within first week following AMI, which may hamper the survival and engraftment of transplanted SCs (ONG & al. [34]; BARTUNEK & al. [35]); (2) the spontaneous myocardial recovery occurs mostly within the first 3–4 months after AMI (POKORNEY & al. [36]); (3) the positive outcome reported when SCs were administered in a later therapeutic window sustained by completed trials such as C-CURE (BARTUNEK & al [30]), CHART-1 (TEERLINK & al. [37]), MYSTAR (GYÖNGYÖSI & al. [38]) and CADUCEUS (MAKKAR & al. [39]); (4) the existence of the ongoing study "The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction" - BAMI (NCT01569178). BAMI is the largest and most ambitious trial to date, aiming to determine if bone marrow-mononuclear cells are a viable option for patients with recent AMI (MATHUR & al. [40]). In the light of the aforementioned consideration, European Society of Cardiology recommended that further research trials in AMI settings should be placed on hold until the final patient outcome data from BAMI will be available (MATHUR & al. [41]).

Still, giving the multifaceted nature of the subject, selecting the optimal timing for SCT remains a challenge. Based on the above data we decided to target the timeframe of 4 weeks to 3 months since the MI, a timeframe when there is little cellular infiltration, collagen synthesis reached the plateau phase with ongoing scar formation and extracellular collagen matrix remodeling.

**Rationale for the designated endpoints**
The study hypotheses ought to be converted in meaningful, well-defined endpoints that comprehend both potential benefits and risks of proposed therapy. Key areas of focus are relieving symptoms, improving health-related quality of life, reducing hospitalization and increasing survival (ALLEN & al. [42]). For an accurate assessment of therapy outcome, evaluation through several parameters from different domains is a prerequisite (DOROBANTU & al. [22]). In this regard, our study complies with observations and recommendations issued by Cardiovascular Cell Therapy Research Network (CCTRN) (HARE & al. [43]). SAFE-HF study will consider every single category of effect acknowledged by CCTRN:
• Structural evaluations: measures of LV function and perfusion;
• Cardiovascular physiological measurements: diastolic performance;
• Biomarkers: markers of systemic inflammation, NT-proBNP, EPCs, MPs;
• Functional capacity: 6-minute walk distance, NYHA classification;
• Health-related quality of life: MLHFQ

As structural evaluations have key roles when assessing SCT benefits, we will use different imaging techniques, namely: 2D and 3D echography, as well as gated Single-Photon Emission Computed Tomography (gated-SPECT).

The echographic parameters to be measured comprise: LVEF, LV volumes, and myocardial deformation. LV volume and LVEF will be calculated with standard 2D, but also with 3D-echocardiography, the new golden-standard of cardiac echography (SPITZER & al. [44]). Considering that many studies using echographic LVEF as surrogate marker did not show significant improvement, we added recent techniques such as strain and tissue Doppler evaluations which have been proved to be more sensitive than global LVEF for the evaluation of SCT (HERBOTS & al. [45]; RUAN & al. [46]).

For the appreciation of infarct size, myocardial viability and perfusion, ECG-gated Tc-99m tetrofosmin SPECT is the technique that will be employed. The gated-SPECT images will be acquired at rest after injection of a body weight-adjusted amount of the aforesaid radiopharmaceutical. Quantitative Perfusion SPECT (QPS) and Quantitative Gated SPECT will be applied by two independent, blinded investigators. We will use the standard 17-segment model of LV in Corridor 4D-MSPECT software which will generate polar maps of the following parameters: perfusion, wall motion and wall thickening. Each LV segment will be scored on a five-point scale (0, normal; 4, absent uptake) as regards the 3 mentioned parameters. Global, as well as regional perfusion, wall motion, and wall thickening will be assessed.

Rationale for a prospective assessment of myocardial viability

Rapid reperfusion of the infarct-related coronary artery is key determinant in rescuing ischemic myocardium and limiting the infarct size in AMI settings. So, assessment of the degree of dysfunctional but viable myocardium is an essential component of the management of patients after AMI. Viable myocardium is represented by 2 entities, both characterized by reversible contractile dysfunction: hibernating and stunned myocardium respectively. In hibernating myocardium ischaemia is still ongoing due to persistently impaired blood flow, whereas in stunned myocardium the coronary blood flow is restored (BRAUNWALD & al. [47]).

Improving functional recovery after AMI is a long-standing desideratum, since loss of viable myocardium prompts negative cardiac remodeling and additional worsening of cardiac function. One of the hypothesized mechanisms for SCs ability to regenerate the failing hearts is
related to enhanced myocardial viability followed by improvement of LVEF and/or limitation of LV remodeling (RONCALLI & al. [48]).

In view of the above arguments, we consider the prospective assessment of myocardial viability a key component in evaluating SCT outcome.

Possible study applications

Stem cell therapy potential to alleviate or even cure a variety of diseases (including cardiovascular ones) represents an enormous economic opportunity. Nevertheless, the regenerative medicine market is still in its commercial formative years worldwide, and particularly in Eastern European countries where there is a stringent need of regulatory and manufacturing capabilities to create and support a feasible product portfolio and technology pipeline in this area. Depending on whether the challenges addressed by our study and other ongoing studies (NCT03227198, NCT03145402, NCT03092284) would be successfully overcome, there are chances that these contribute to the foundation of new technologies and companies.

Study Strengths

1. Comprehensive assessment of endpoints from different categories;
2. First study to exploit circulating endothelial progenitor cells and microparticles as surrogate markers of endothelial dysfunction and procoagulant status after SCT in HF.

Study Limitations

First, the optimal number of BMMNCs and CD34+ progenitors to be transplanted is yet to be determined, since the existing evidence is contradictory, with some studies reporting that a lower cell dosage would be the most efficient, and others stating either an inverse or nonlinear relationship (GOLPANIAN & al. [49]). Notably, there is a significant individual variability related to the number and function of SCs with age and cardiovascular risk factors, leading to reduced effectiveness of SCT especially in patients who need it the most. Prior data from our laboratory indicate that the mean number of mononuclear cells obtained from 50 ml of bone marrow aspirate was roughly $10^8$, with a mean percentage of CD34+ cells of 0.62 ± 0.36% (MICHEU & al. [50]). In studies evaluating the effect of transplanted cells on myocardial function in a dose-dependent manner, this number of cells was considered high dose and also efficient (MELUZÍN & al. [51]). Similarly, a meta-analysis based on 40 randomized controlled trials and 1927 patients reported that doses between $10^8$ and $10^9$ cells were efficient in improving LVEF in AMI patients (as opposed to lower or higher dose) (XU & al. [52]).

Secondly, another possible limitation could be related to the route of administration, as injected cells can be easily washed-out. In order to overcome the poor retention of cells we will deliver the cells by a stop-flow technique using balloon occlusion followed by reperfusion. But an advantage not to forget of is that intracoronary administration enables relatively homogenous dissemination of cells in the target area.

Thirdly, due to resource and time constraints, our study will include only a limited number of patients, followed-up for 3 months. However, since long term effects of SC therapy are not well known, we intend to further follow-up the patients enrolled, pending additional funding.
4. Acknowledgements

This work was supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNCS/CCCDI UEFISCDI, project number PN-III-P2-2.1-PED-2016-1333, within PNCDI III.

References


